ReviewDiabetologia2025
Glycaemic control is still central in the hierarchy of priorities in type 2 diabetes management.
Review in Diabetologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Effects of digital and remote exercise interventions on HbA1c in type 2 diabetes: a systematic review and network meta-analysis.BMC endocrine disorders · 2026Pooled it
- Weight Changes With Tirzepatide and Concomitant Weight-Inducing Medications: Post Hoc Analysis of Randomized Clinical Trials.JAMA network open · 2026Pooled it
- Nutrient intake order on metabolic outcomes in type 2 diabetes: a systematic review and meta-analysis.Acta diabetologica · 2026Pooled it
- Efficacy and safety of traditional Chinese classic prescriptions combined with metformin in the treatment of type 2 diabetes mellitus: a Bayesian network meta-analysis.Frontiers in pharmacology · 2026Pooled it
- A 7-year prospective analysis of sustained benefits of multicomponent risk assessment and data-driven care in patients with type 2 diabetes: The Malaysian JADE Program.Diabetes, obesity & metabolism · 2025Trial
- Glycemic status, antioxidant enzyme and lipid peroxidation among patients with diabetes mellitus in Buea Regional Hospital in Cameroon.World journal of biological chemistry · 2026Article
- Cost-effectiveness analysis comparing real-time continuous glucose monitoring with self-monitoring of blood glucose for patients with type 2 diabetes treated with insulin in Japan.Journal of diabetes investigation · 2026Article
- Fixed-Dose Combination Therapy as a Strategy to Improve Antidiabetic Medication Adherence in People with Type 2 Diabetes: A Narrative Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Review
- Cost-effectiveness analysis of Dexcom ONE+ real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with type 2 diabetes in Aotearoa New Zealand.Diabetes, obesity & metabolism · 2026Article
- Role of Sleep Disturbances and Diabetes-Related Distress on Glycemic Control: A Path Analysis.Research in nursing & health · 2026Article
- Mechanisms and Production of Hypoglycaemic Peptides: Exploring the Potential ofFood science & nutrition · 2026Review
- Phenotypic heterogeneity and polygenic risk scores in a family of maturity-onset diabetes of the young.JCEM case reports · 2026Article
- A High-Precision Screen-Printed Glucose Sensor with In Situ Impedance-Based HCT Correction and Temperature Compensation.Biosensors · 2026Article
- Type 2 diabetes mellitus.Nature reviews. Disease primers · 2026Review
- A bimodal dataset for diabetes research.Scientific data · 2026Article
- Baseline metabolite profiles predict the glucose-lowering efficacy of exenatide in patients with type 2 diabetes.Metabolism open · 2026Article
- Nonlinear Association Between THs, TSH, and HbA1c in Patients With Type 2 Diabetes Mellitus: A Retrospective Study.Journal of diabetes · 2026Article
- Diabetes Mellitus as an Integrated Microbiome, Immune, and Metabolic Disorder with Clinical Implications for Multisystem Complications and Public Health.Journal of clinical medicine · 2026Review
- Systemic effects of type 2 diabetes therapies: an integrated perspective on the cardio-renal- cerebral-metabolic axis.Frontiers in medicine · 2026Review
- The Impact of the Multidisciplinary Team on Medication Adherence in Type 2 Diabetes: A Narrative Review.Journal of multidisciplinary healthcare · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A panel of primary care and diabetes specialists conducted focused literature searches on the current role of glycaemic control in the management of type 2 diabetes and revisited the evolution of evidence supporting the importance of early and intensive blood glucose control as a central strategy to reduce the risk of adverse long-term outcomes. The optimal approach to type 2 diabetes management has evolved over time as the evidence base has expanded from data from trials that established the role of optimising glycaemic control to recent data from cardiovascular outcomes trials (CVOTs) demonstrating organ-protective effects of newer glucose-lowering drugs (GLDs). The results from these CVOTs were derived mainly from people with type 2 diabetes and prior cardiovascular and kidney disease or multiple risk factors. In more recent years, earlier diagnosis in high-risk individuals has contributed to the large proportion of people with type 2 diabetes who do not have complications. In these individuals, a legacy effect of early and optimal control of blood glucose and cardiometabolic risk factors has been proven to reduce cardiovascular and kidney disease events and all-cause mortality. As there is a lack of RCTs investigating the potential synergistic effects of intensive glucose control and organ-protective effects of newer GLDs, this article re-evaluates the evolution of the scientific evidence and highlights the importance of integrating glycaemic control as a pivotal early therapeutic goal in most people with type 2 diabetes, while targeting existing cardiovascular and kidney disease. We also emphasise the importance of implementing multifactorial management using a multidisciplinary approach to facilitate regular review, patient empowerment and the possibility of tailoring interventions to account for the heterogeneity of type 2 diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.